Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM62UHC)

• Drug Name: Meropenem Drug Info
• Synonyms: MEPM; MERONEM; Meropen; Merrem; Meropenem anhydrous; Mepem (TN); Meronem (TN); Meropen (TN); Meropenem (INN); Merrem (TN); Neopenem (TN); SM-7338; Meronem; Merrem I.V. (TN); (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; (2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid
• Therapeutic Class: Antibiotics
• Cross-matching ID:
  PubChem CID: 441130
  ChEBI ID: CHEMBL43968
  CAS Number: CAS 96036-03-2
  TTD Drug ID: D0O5FY
  VARIDT Drug ID: DR01200
  INTEDE Drug ID: DR2491

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	2.31	0.00e+0	34/36 (94.44%)	PCNA;MCM7;RFC5;...
Malaria	1.80	4.45e-2	44/50 (88%)	CXCL8;COMP;THBS4;...
VEGF signaling pathway	-1.67	2.88e-2	50/59 (84.75%)	PPP3CB;MAPKAPK2;KRAS;...
beta-Alanine metabolism	-1.76	1.47e-2	25/30 (83.33%)	ALDH7A1;ALDH3B1;ALDH3A1;...
Tyrosine metabolism	-1.78	1.11e-2	30/36 (83.33%)	ADH1A;ALDH3B1;ALDH3A1;...
Arginine and proline metabolism	-1.78	1.15e-2	39/50 (78%)	ARG1;GATM;PYCR1;...
Bile secretion	-1.78	1.20e-2	68/90 (75.56%)	RXRA;AQP4;SLC10A1;...
Ascorbate and aldarate metabolism	-1.80	1.08e-2	15/30 (50%)	UGT2B17;UGT2B15;RGN;...
Autophagy	-1.82	6.49e-3	113/169 (66.86%)	MTMR14;SH3GLB1;GABARAPL2;...
Mitophagy	-1.83	4.31e-3	56/68 (82.35%)	HRAS;MFN2;TAX1BP1;...
Cholesterol metabolism	-1.83	4.51e-3	44/50 (88%)	CYP27A1;ANGPTL4;APOH;...
Glycolysis / Gluconeogenesis	-1.83	4.72e-3	56/67 (83.58%)	DLAT;ALDH7A1;LDHB;...
Chemical carcinogenesis	-1.83	4.96e-3	186/281 (66.19%)	ADRB2;GSTO1;UGT2B4;...
Ether lipid metabolism	-1.83	5.22e-3	32/49 (65.31%)	PAFAH1B1;CEPT1;PLD1;...
Protein processing in endoplasmic reticulum	-1.86	4.72e-3	127/171 (74.27%)	MAPK9;DDOST;SSR1;...
Propanoate metabolism	-1.86	5.00e-3	30/34 (88.24%)	MMUT;ACADS;SUCLG2;...
Fatty acid degradation	-1.87	5.31e-3	40/43 (93.02%)	ACADL;ALDH7A1;ADH1A;...
Proximal tubule bicarbonate reclamation	-1.88	5.67e-3	21/23 (91.3%)	ATP1B1;FXYD2;CA4;...
Drug metabolism	-1.90	4.05e-3	78/151 (51.66%)	CYP2C19;MGST2;NAT1;...
Mineral absorption	-1.91	4.36e-3	48/60 (80%)	SLC34A2;SLC8A2;ATP1A2;...
Pyruvate metabolism	-1.92	4.72e-3	41/47 (87.23%)	GLO1;DLD;MDH1;...
Folate biosynthesis	-1.94	2.58e-3	23/26 (88.46%)	MOCOS;GCH1;AKR1B1;...
Renin-angiotensin system	-2.00	1.42e-3	20/23 (86.96%)	ENPEP;ATP6AP2;MME;...
Histidine metabolism	-2.02	0.00e+0	16/22 (72.73%)	ALDH7A1;ALDH3B1;ALDH3A1;...
Nitrogen metabolism	-2.04	0.00e+0	16/17 (94.12%)	GLUD2;CPS1;GLUD1;...
Valine, leucine and isoleucine degradation	-2.04	0.00e+0	42/48 (87.5%)	BCAT2;MMUT;HADHB;...
Metabolism of xenobiotics by cytochrome P450	-2.07	0.00e+0	49/77 (63.64%)	ADH7;MGST3;CYP2A13;...
Fat digestion and absorption	-2.09	0.00e+0	35/43 (81.4%)	MTTP;PLPP3;PLPP1;...
Steroid hormone biosynthesis	-2.10	0.00e+0	43/61 (70.49%)	CYP11B1;HSD3B1;UGT2B4;...
Retinol metabolism	-2.11	0.00e+0	41/68 (60.29%)	UGT2B4;ADH6;UGT2B28;...
PPAR signaling pathway	-2.11	0.00e+0	66/74 (89.19%)	PLIN1;ILK;ACADM;...
Tryptophan metabolism	-2.19	0.00e+0	35/42 (83.33%)	TDO2;ACAT2;DLST;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Hide ▲

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H	Show ▼

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	8uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼